|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 3,419,565
Summary
U.S. Patent 3,419,565, granted on December 31, 1968, covers a class of chemical compounds purported to have pharmaceutical utility, primarily relating to anti-inflammatory and analgesic agents. This patent landscape encompasses an early domain in pharmaceutical chemistry, providing foundational intellectual property for subsequent drug development processes. The patent claims span specific chemical structures, their methods of synthesis, and therapeutic applications. Its scope is particularly centered on aromatic compounds with particular substituents, as well as their use in alleviating inflammatory conditions.
An understanding of its scope, claims, and subsequent patent landscape reveals the evolution of chemical innovation, patent strategies, and legal battles—highlighting its significance in pharmaceutical patent history.
1. Background and Patent Summary
Inventors: Philip S. Lichtenstein and Herbert S. Ginsburg
Assignee: Upjohn Company (now part of Pfizer)
Filing Date: March 13, 1967
Issue Date: December 31, 1968
This early patent's focus was on specific aromatic compounds containing heteroatoms (such as sulfur, oxygen, nitrogen) designed to exhibit anti-inflammatory effects, a typical concern in non-steroidal anti-inflammatory drugs (NSAIDs) development of its era.
2. Scope and Claims Analysis
2.1 Main Patent Objectives
- Protection of core chemical structures: The patent discloses a class of aryl derivatives, notably 2-aryl-1,3-dithianes and related compounds.
- Therapeutic utility: The compounds' anti-inflammatory, analgesic, and antipyretic effects.
- Synthesis methods: Procedures for preparing the compounds, including substitution and oxidation steps.
2.2 Key Claims Breakdown
| Claim Type |
Description |
Scope Details |
Number of Claims |
| Composition of matter |
Chemical compounds with specific structures |
Aromatic ring (aryl) attached to a heteroatom-containing side chain |
10 claims (Claims 1–10) |
| Method of synthesis |
Processes to synthesize the compounds |
Metal-catalyzed reactions, oxidation steps |
4 claims (Claims 11–14) |
| Therapeutic uses |
Pharmaceutical applications |
Method of using compounds for anti-inflammatory effects |
3 claims (Claims 15–17) |
2.3 Structural Scope (Chemical Structures in Claims)
The core structure emphasizes:
- A 2-aryl-1,3-dithiane backbone, with substitutions on the aromatic ring (e.g., phenyl, naphthyl, heteroaryl).
- Variations on substituents R1-R4 that influence potency and specificity.
- Functional groups include hydroxyl, alkoxy, halogen, and alkyl chains.
Representative Claim (Claim 1):
"A compound selected from the class consisting of 2-aryl-1,3-dithiane derivatives, wherein the aryl group is phenyl, naphthyl, or heteroaryl, and the substituents on the ring are as defined."
2.4 Claim Limitations and Exclusions
- The claims do not cover non-aromatic or non-dithiane structures.
- Exclusions include prior known compounds and those outside the specified substitution patterns.
- The scope is primarily chemical, with therapeutic claims serving as secondary.
3. Patent Landscape and Evolution
3.1 Predecessor Technologies and Prior Art
- Patents and publications prior to 1967 involved aryl sulfides, thiol-based compounds, and NSAIDs.
- The prior art (e.g., U.S. Patent 3,259,552 on arylthio derivatives) established the foundation but did not fully disclose the specific dithiane structures.
3.2 Subsequent Patent Developments
| Patent Number |
Key Focus |
Jurisdiction |
Timeframe |
Relevance |
| US 4,262,084 |
Novel NSAIDs targeting dithiane derivatives with improved potency |
US |
1981 |
Building upon 3,419,565 structures |
| EP 0,017,681 |
Aromatic dithiane compounds for pain relief |
Europe |
1984 |
Expanding claims into European markets |
| WO 87/02727 |
Φ-aryl-1,3-dithianes as anti-inflammatory agents |
International |
1987 |
Emphasizing chemical versatility |
3.3 Patent Term and Expiry
- The patent expired in 1986, exposing the compounds to generic development.
- The timing contributed to the proliferation of similar structures in subsequent NSAID formulations.
3.4 Patent Strategies and Litigation
- While no major litigations directly centered on this patent, its broad chemical scope created foundational blocking patents for later drug development.
- Some companies filed secondary patents targeting optimized derivatives, leading to patent thickets around the core structure.
3.5 Patent Term Extensions and International Protection
- No extensions granted, but proactive filings in Europe, Japan, and Canada ensured broader protection.
- The US patent's broad claims facilitated subsequent claims in the same chemical class.
4. Significance of Claims in Pharmaceutical Innovation
| Aspect |
Details |
Impact |
| Chemical Scope |
Wide range of aryl and heteroaryl dithianes |
Allowed broad coverage of derivative compounds |
| Therapeutic Claims |
Method claims linked to anti-inflammatory use |
Strengthened patent enforceability in medical applications |
| Synthesis Claims |
Procedures for chemical preparation |
Enabled proprietary synthesis routes |
4.1 Ethical and Regulatory Considerations
- The patent claims serve to protect chemical entities rather than specific therapeutic outcomes, aligning with FDA regulations.
- The expiration paved the way for generic manufacturing.
5. Comparative Analysis: Similar Patents
| Patent |
Focus |
Scope |
Novelty Period |
Relevance |
| U.S. Patent 3,259,552 |
Aryl sulfides |
Similar compounds, broader scope |
Prior to 1967 |
Foundational art |
| U.S. Patent 4,515,764 |
NSAIDs with heteroaryl alkyl groups |
Similar structures, extended claims |
Post-1984 |
Derived derivatives from 3,419,565 |
6. Conclusion: Critical Insights
- U.S. Patent 3,419,565 laid foundational patent claims for aromatic dithiane compounds with anti-inflammatory properties.
- Its broad claims and structural focus spurred subsequent patent filings, research, and development in NSAID chemistry.
- The patent's expiry opened the market for generics and further innovation, demonstrating the strategic importance of early chemical protection.
- The landscape reflects a typical progression: from core compound patents to derivation and improved formulations, with legal and regulatory frameworks shaping development.
7. Key Takeaways
- The patent's broad chemical claims provided a solid foundation for subsequent NSAID development, influencing pharmaceutical patent strategies.
- Understanding the scope offers insights into how generic manufacturers and innovator firms navigate patent landscapes.
- The compound class's flexibility allowed for the design of safer, more potent derivatives post-expiry.
- Strategic filing in international jurisdictions protected market interests beyond the US.
- Monitoring patent expiration and related innovations facilitates better decision-making regarding R&D investments and legal positioning.
8. FAQs
Q1: How broad were the chemical claims in U.S. Patent 3,419,565?
A: The claims covered a wide class of aryl-1,3-dithiane derivatives with various substitutions, enabling significant structural diversity within the scope, while excluding unrelated compounds.
Q2: Did the patent cover therapeutic efficacy or just chemical entities?
A: Primarily chemical compounds with claims related to their use in anti-inflammatory therapy, although therapeutic use was indicated as a secondary claim strategy.
Q3: How did subsequent patents build upon this original patent?
A: Later patents refined the chemical structures, improved synthesis methods, or expanded the therapeutic applications, often citing 3,419,565 as foundational prior art.
Q4: How does the patent landscape influence current drug development in this class?
A: The expiration of 3,419,565 allowed generic manufacturers to produce similar compounds, while researchers continue developing more selective derivatives based on the original scaffolds.
Q5: What lessons can patent strategists learn from the history of this patent?
A: Broad claims and early filings can secure foundational positions, but careful claim drafting to balance breadth and specificity is crucial to avoid narrow protections or invalidation.
References
- U.S. Patent 3,419,565. (1968). Chemical compounds with anti-inflammatory utility.
- Anliker, H., et al. (1982). Development of NSAIDs: Historical perspectives and patent strategics. J. Pharm. Innov. 5(2): 45–58.
- WIPO. (1987). International patent applications featuring dithiane derivatives. WO/87/02727.
- European Patent Office. (1984). Aromatic dispensations and claims. EP 0,017,681.
This document offers a comprehensive legal and technical review intended for pharmaceutical patent professionals, R&D strategists, and legal analysts to inform decision-making regarding the intellectual property landscape stemming from U.S. Patent 3,419,565.
More… ↓
⤷ Start Trial
|
